Metsera, Inc. Reports Positive Phase 1 Trial Results

An update from Metsera, Inc. ( (MTSR) ) is now available.

On June 9, 2025, Metsera, Inc. announced the results of its Phase 1 clinical trial for MET-233i, an injectable ultra-long acting amylin analog aimed at treating obesity and overweight. The trial, which included single and multiple ascending dose portions, primarily focused on the safety and tolerability of MET-233i, showing it to be generally well-tolerated with dose-dependent gastrointestinal-related adverse events. The trial also demonstrated dose-dependent weight loss, with significant placebo-subtracted weight loss observed in both single and multiple dose cohorts. These positive results support the advancement of MET-233i as a potential monotherapy and in combination with MET-097i, with further trials and data expected by late 2025.

The most recent analyst rating on (MTSR) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.

Spark’s Take on MTSR Stock

According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.

Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.

To see Spark’s full report on MTSR stock, click here.

More about Metsera, Inc.

Average Trading Volume: 972,813

Current Market Cap: $2.89B

Learn more about MTSR stock on TipRanks’ Stock Analysis page.